NanoCarrier Co. Ltd risk profile
58 Elevated one input has moved against it
Measured 1 September 2026 from 3NQ's filed statements. Recomputed nightly.
58 (Elevated), driven by Competitive position at 91, over 4 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 85 | Acute | Stable | Drawdown from the 52-week high — 53.0% |
| Operating pressure | 0 | Contained | Easing | Costs outgrowing revenue — -28.8 percentage points |
| Cash conversion | Reads operating_cashflow, capital_expenditure, free_cashflow, net_income and revenue. No reading is stored for this company. | |||
| Leverage and coverage | 35 | Normal | Worsening | Interest cover — -39.64x |
| Competitive position | 91 | Acute | Stable | Operating-margin gap against peers — -458.3 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 17Johnson & Johnson 37Abbvie Inc 46Roche Holding AG 32Merck & Co Inc 26Novartis AG 25Astrazeneca plc 30AMGEN Inc 33Thermo Fisher Scientific Inc 45Novo Nordisk A/S 23Abbott Laboratories 43Gilead Sciences Inc 31
Financials, valuation and price history for NanoCarrier Co. Ltd